Navigation Links
Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R)
Date:12/16/2008

l at IR@novacea.com or by telephone at (650) 228-1800. Investors and security holders are urged to read the proxy statement/prospectus/information statement and the other relevant materials before making any voting or investment decision with respect to the proposed transaction.

Novacea and its respective directors and executive officers may be deemed to be participants in the solicitation of proxies from its stockholders in favor of the proposed transaction. Information about the directors and executive officers of Novacea and their respective interests in the proposed transaction is available in the proxy statement/prospectus/information statement.

SafeHarbor

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Transcept and Novacea disclaim any intent or obligation to update these forward-looking statements, and claim the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the expected timing of potential U.S. Food and Drug Administration (FDA) approval of Intermezzo(R); and the expected timing of commercialization and launch of Intermezzo(R); and the expected benefits of Transcept product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, failure of Novacea stockholders to approve the merger; Novacea or Transcept inability to satisfy the conditions of the merger, or that the merger is otherwise delayed or ultimately not consummated; the rates of use of Transcept and Novacea cash and cash equivalents prior to the closing of
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Transcept Pharmaceuticals to Participate in Middle-of-the-Night (MOTN) Insomnia Investor Panel
2. Transcept Pharmaceuticals Appoints Key Senior Executives
3. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... OMICS Group International invites researchers, authors and ... ‘Open Access Week’ by actively contributing their research ... Journals from 20-26th October, 2014. , Pharmaceutical ... accelerating with a tremendous speed to provide improved ... industry is gearing with innovation and technological revolution ...
(Date:9/18/2014)... 2014 SeqLL Inc., the owner ... announced today the closing of a $1M Series-A ... Genomic Diagnostic Technologies, will increase the power of ... Founded in March 2013 by Daniel Jones, a ... Helicos BioSciences, SeqLL has continued to offer Helicos’ ...
(Date:9/18/2014)... group of rare diseases that afflict skeletal growth ... hits at the fetal stage and is caused ... encoding fibroblast growth factor receptor 3 (FGFR3) has ... thanatophoric dysplasia (TD), a skeletal dysplasia that cause ... lethal, and achondroplasia (ACH), which causes stunted growth ...
(Date:9/18/2014)... Furnishing a research lab can be pretty expensive. Now ... University has published an open-source library of designs that ... used piece of equipment: the syringe pump. , Syringe ... as for drug delivery or mixing chemicals in a ... of dollars. , Joshua Pearce and his team of ...
Breaking Biology Technology:Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3Doing science just got cheaper -- and faster 2
... Calif., June 6 InterMune, Inc.,(Nasdaq: ITMN ) ... Financial Officer of InterMune, will present at the Goldman ... on,June 10, 2008 at 8:05 a.m. PDT (11:05 a.m. ... Needham & Company, LLC Biotechnology and,Medical Technology Conference in ...
... 5 BioTrends Research Group, Inc.,released its third ... management of psoriasis. This report is based on,responses ... Dermatologists in April,2008., According to the study, ... use of biologics for the treatment of psoriasis ...
... BioTrends Research Group, Inc. is,pleased to announce the ... is based on the results of an on-line ... France, Germany, Italy, and Spain.,The report focuses on ... In the ESA market, Amgen,s Aranesp is ...
Cached Biology Technology:InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences 2Dermatologists Report Increased Use of Biologics in the Treatment of Psoriasis 2New Study by BioTrends Highlights Practice Management Shifts Among European Nephrologists 2
(Date:9/18/2014)... that when people are too stressed they are often ... Brain Mind Institute (BMI) at EPFL have just highlighted ... chronic stress and the loss of social skills and ... a synaptic regulatory molecule in the brain. This was ... . , Carmen Sandi,s team went to look ...
(Date:9/18/2014)... the roaches of the fish world, are the ideal ... body shape. They,ve moved from the ocean into tens ... world, each time changing their skeleton to adapt to ... freshwater populations of sticklebacks now have turned up one ... that a simple change in that gene,s regulation in ...
(Date:9/18/2014)... the ultimate form of camouflage: you don,t just blend ... is not as uncommon as you might think. Kathryn ... explains that the larval life stages of many marine ... the anatomy that most creatures cannot make transparent. Feller ... shield each individual eye unit with an opaque pigment ...
Breaking Biology News(10 mins):How stress tears us apart 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3Transparent larvae hide opaque eyes behind reflections 2
... the results of the Oats at 10 Years study, marking ... claim that oats, as part of an overall heart healthy ... written by Mark B. Andon, PhD, and James W. Anderson, ... claim, theorizing that foods containing whole-oat sources of soluble fiber ...
... University bioengineer Jennifer West is being recognized today with ... the O,Donnell Award from The Academy of Medicine, Engineering ... given for excellence in medical, scientific and engineering research, ... statue. West, a pioneer in the field of biomaterials ...
... of Alberta for those who may have overindulged during the recent ... a way to reduce the amount of bad cholesterol and fatty ... metabolizes, a key discovery that could lead to new drugs to ... disease related to obesity. In a series of recently ...
Cached Biology News:Rice's West honored as one of Texas' best researchers 2Rice's West honored as one of Texas' best researchers 3University of Alberta researchers report breakthrough in lowering bad cholesterol, fatty acid levels 2
... The Sub-Plates are E.Coli glycerol stocks contained ... contains 50 cDNA clones with approximately 5,000 ... the a master plate well, the corresponding ... PCR to identify the positive well(s). Cells ...
... 0.9 ml per liter of urine will give ... or BMD dipstick. ,Certification: The Donors are ... found to be NEGATIVE for HbsAg, HCV, HIV-1 ... approved FDA methods. THIS MATERIAL IS SOLD FOR ...
One controller two vessel system suitable for early stage of fermentation, and small scale, Application : cultivation of microorganisms and human or animal cells...
... light production by luciferase-cDNA transfected cell lines ... in the development of reporter gene assays ... an indicator for the transcription of other ... is due to advantages such as high ...
Biology Products: